5th Apr 2016 08:40
LONDON (Alliance News) - Proteome Sciences PLC on Tuesday welcomed two recent reports emphasising the importance of using protein profiling in improving the outcomes of cancer treatment.
Proteome, which makes technology to map and analyse protein changes, said the first of the two studies, by University College London and Cancer Research UK, found genetic mutations in cancer can lead to changes in proteins on the cell surface.
Studies into the response shown by lung cancer patients highlighted a need for deeper analysis of protein expressions in tumours in order to better understand the mechanism that contribute to treatment failing, Proteome said.
The second study, led by Manchester University's Nigel Bundred, found use of two drugs which act on the same breast cancer target, an over-expressing protein called Her-2, were able to eradicate detectable tumours in around 10% of patients in about 11 days, with 87% of those treated experiencing a proteomic change, indicating cells had stopped growing or cell death had increased.
"Both these recent studies should rightly be recognised as important steps forward towards better cancer treatment," said Ian Pike, Proteome's chief operating officer.
"However, in order to overcome the limitations of current drug therapy programmes, a much deeper and more comprehensive analysis of the complex protein networks that regulate tumour growth and survival is required and will be essential to achieve a major advance in the battle to treat cancer," he added.
Proteome shares were up 0.8% to 15.75 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Proteome